Are NMDA receptor antagonists beneficial in the treatment of schizophrenia?

[1]  N. Iwata,et al.  Efficacy and safety of NMDA receptor antagonists augmentation therapy for schizophrenia: an updated meta-analysis of randomized placebo-controlled trials. , 2013, Journal of psychiatric research.

[2]  Taro Kishi,et al.  NMDA receptor antagonists interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled trials. , 2013, Journal of psychiatric research.

[3]  S. Akhondzadeh,et al.  Memantine Add-On to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study , 2013, Journal of clinical psychopharmacology.

[4]  Young Hoon Kim,et al.  Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study , 2012, Psychiatry investigation.

[5]  K. Tan-No,et al.  Pharmacological characterizations of memantine-induced disruption of prepulse inhibition of the acoustic startle response in mice: Involvement of dopamine D2 and 5-HT2A receptors , 2011, Behavioural Brain Research.

[6]  G. Tsai,et al.  Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. , 2010, Current pharmaceutical design.

[7]  M. Berk,et al.  Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. , 2009, The Journal of clinical psychiatry.

[8]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[9]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[10]  J. Lieberman,et al.  A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia , 2009, Neuropsychopharmacology.

[11]  Denise O'Connor,et al.  Chapter 5: Defining the review question and developing criteria for including studies , 2008 .

[12]  Michael W Kattan,et al.  Meta-analysis: Its strengths and limitations. , 2008, Cleveland Clinic journal of medicine.

[13]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[14]  H. Silver,et al.  A double-blind, cross-over comparison of the effects of amantadine or placebo on visuomotor and cognitive function in medicated schizophrenia patients , 2005, International clinical psychopharmacology.

[15]  M. Rossor,et al.  Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine , 2005, Neurology.

[16]  D. Jeste,et al.  Use of the mini-mental state exam in middle-aged and older outpatients with schizophrenia: cognitive impairment and its associations. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[17]  B. Platt,et al.  Glutamate receptor function in learning and memory , 2003, Behavioural Brain Research.

[18]  S. Kuzuhara.  Drug-induced psychotic symptoms in Parkinson's disease. Problems, management and dilemma , 2001, Journal of Neurology.

[19]  S. Yusuf,et al.  Strengths and limitations of meta-analysis: larger studies may be more reliable. , 1997, Controlled clinical trials.

[20]  K. Toide.  Effects of Amantadine on Dopaminergic Neurons in Discrete Regions of the Rat Brain , 1990, Pharmaceutical Research.

[21]  Philip D. Harvey.  Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants. , 2012, Handbook of clinical neurology.